Literature DB >> 30142634

Establishing Sustainable Cardiothoracic Surgery Programs in Underserved Countries.

Kathleen Fenton1, Marcelo Cardarelli1, Frank Molloy1, William Novick1.   

Abstract

Congenital heart disease is the most common birth defect worldwide, and accounts for a high proportion of the world's infant mortality. About 9 of every 10 babies born each year are born in areas without adequate access to heart surgery; overcoming this problem will necessitate addressing the worldwide shortage of an estimated 3,700 pediatric cardiac surgeons. Establishing sustainable heart surgery programs requires more than an investment of money: political, social, and cultural issues unique to each environment need to be addressed. Organizations desiring to help develop cardiac surgical centers need to focus on communication and bidirectional education, and to make a long-term commitment to each site. By identifying and addressing obstacles, success rates are high. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2018        PMID: 30142634     DOI: 10.1055/s-0038-1668598

Source DB:  PubMed          Journal:  Thorac Cardiovasc Surg        ISSN: 0171-6425            Impact factor:   1.827


  3 in total

1.  Global health initiatives in cardiothoracic surgery: Ethical considerations and guidelines.

Authors:  Kathleen N Fenton; William M Novick; John W Entwistle; Susan D Moffatt-Bruce; Robert M Sade
Journal:  J Thorac Cardiovasc Surg       Date:  2020-10-16       Impact factor: 6.439

2.  Cost-effectiveness of Humanitarian Pediatric Cardiac Surgery Programs in Low- and Middle-Income Countries.

Authors:  Marcelo Cardarelli; Sumeet Vaikunth; Katie Mills; Thomas DiSessa; Frank Molloy; Elizabeth Sauter; Karen Bowtell; Roslyn Rivera; Andrew Y Shin; William Novick
Journal:  JAMA Netw Open       Date:  2018-11-02

3.  Mortality for Critical Congenital Heart Diseases and Associated Risk Factors in Newborns. A Cohort Study.

Authors:  Andressa Mussi Soares
Journal:  Arq Bras Cardiol       Date:  2018-11       Impact factor: 2.000

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.